BREYANZI
Bristol Myers Squibb’s Bold Robotic Alliance with Cellares for Advanced CAR-T Production
Anika Sharma
In the realm of cutting-edge cell therapy, where innovation is the heartbeat and the promise of transformative treatments is the ...
ASCO 2023: BREYANZI Shines as First CAR T Therapy with Deep and Lasting Impact in Chronic Lymphocytic Leukemia
SG Tylor
The initial findings from the important TRANSCEND CLL 004 study, which is evaluating the use of BREYANZI (lisocabtagene maraleucel) in ...
